clofibric acid has been researched along with Diabetes Mellitus, Type 2 in 54 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effect of etofibrate on the LDL-subtype distribution in patients with type 2 diabetes mellitus (n = 13, 55 +/- 18 years, BMI 27." | 5.10 | Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. ( Dietlein, M; Geiss, HC; Parhofer, KG, 2003) |
| "When treated with atorvastatin, 90% of patients achieved a LDL C<1 g/L, compared to 51% when treated with fibrate (P=0." | 2.74 | Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. ( Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M, 2009) |
| "Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action." | 2.69 | Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. ( Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E, 2000) |
| "Clofibric acid was only effective in reducing triglycerides." | 2.67 | Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. ( Dude, H; Fischer, S; Hanefeld, M; Julius, U; Rothe, G; Schmechel, H; Schulze, J; Schwanebeck, U, 1991) |
| "All patients with type 2 diabetes should reach an LDL cholesterol of <100 mg/dl, the very-high risk patients with both diabetes and coronary artery disease an LDL cholesterol <70 mg/dl." | 2.46 | [Lipid therapy in patients with diabetes]. ( Drexel, H; Saely, CH, 2010) |
| "Vascular complications associated with type 2 diabetes confer significant morbidity and mortality." | 2.44 | Atherosclerosis in type 2 diabetes: a role for fibrate therapy? ( Steiner, G, 2007) |
| "Greater than 60% of patients with type 2 diabetes will have retinopathy." | 2.44 | Update on the treatment of diabetic retinopathy. ( Miller, AG; Wilkinson-Berka, JL, 2008) |
| "Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors." | 2.44 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. ( Gerich, JE, 2007) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Eight trials and 12 249 patients with type 2 diabetes were included in the analyses." | 2.43 | Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. ( Allemann, S; Christ, ER; Diem, P; Egger, M; Stettler, C, 2006) |
| "Patients with metabolic syndrome and type 2 diabetes mellitus are usually in moderately high-risk, high-risk, or very high-risk cardiovascular categories and present major therapeutic challenges." | 2.43 | Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. ( Dayspring, T; Pokrywka, G, 2006) |
| "Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL." | 2.42 | LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? ( Taskinen, MR, 2003) |
| "The metabolic syndrome is commonly encountered in the United States." | 2.42 | Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. ( Reasner, CA; Rosenson, RS, 2004) |
| "Although type 2 diabetes is associated with a clustering of risk factors, the cause for an excess risk of cardiovascular disease remains unknown." | 2.41 | Lipids in type 2 diabetes. ( Laakso, M, 2002) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "The metabolic syndrome is a cluster of symptoms that function as risk factors for cardiovascular disease (CVD), and its key components--diabetes, dyslipidemia, and hypertension--form a lethal combination." | 1.36 | Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. ( Mehta, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 3 (5.56) | 18.2507 |
| 2000's | 43 (79.63) | 29.6817 |
| 2010's | 7 (12.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Staels, B | 3 |
| Maes, M | 1 |
| Zambon, A | 1 |
| Davidson, M | 1 |
| Ansquer, JC | 1 |
| Foucher, C | 1 |
| Aubonnet, P | 1 |
| Le Malicot, K | 1 |
| Saha, SA | 1 |
| Arora, RR | 1 |
| Meas, T | 1 |
| Laloi-Michelin, M | 1 |
| Virally, M | 1 |
| Peynet, J | 1 |
| Giraudeaux, V | 1 |
| Kévorkian, JP | 1 |
| Guillausseau, PJ | 1 |
| Merkel, M | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Cybulska, B | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Nakajima, K | 1 |
| Saely, CH | 1 |
| Drexel, H | 1 |
| Lalloyer, F | 1 |
| Mehta, A | 1 |
| Jialal, I | 1 |
| Amess, W | 1 |
| Kaur, M | 1 |
| Ruiz, J | 1 |
| Taskinen, MR | 2 |
| Geiss, HC | 2 |
| Dietlein, M | 1 |
| Parhofer, KG | 1 |
| Wierzbicki, AS | 3 |
| Mikhailidis, DP | 1 |
| Wray, R | 1 |
| Rosenson, RS | 2 |
| Reasner, CA | 1 |
| Vergès, B | 2 |
| Hanefeld, M | 3 |
| Fruchart, JC | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Herman, ZS | 1 |
| Candido, R | 1 |
| Zanetti, M | 1 |
| Laakso, M | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Madaliński, M | 1 |
| Rutkowski, B | 1 |
| Cylkowska, B | 1 |
| Rutkowski, P | 1 |
| Wiśniewski, M | 1 |
| Hajduk, A | 1 |
| Davidson, MH | 1 |
| Allemann, S | 1 |
| Diem, P | 1 |
| Egger, M | 1 |
| Christ, ER | 1 |
| Stettler, C | 1 |
| Charlton-Menys, V | 1 |
| Durrington, P | 1 |
| Parhofer, K | 1 |
| Touyz, RM | 1 |
| Schiffrin, EL | 1 |
| Dayspring, T | 1 |
| Pokrywka, G | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Motro, M | 1 |
| Adler, Y | 1 |
| Gouni-Berthold, I | 1 |
| Krone, W | 1 |
| Konstantinov, VO | 1 |
| Saĭfulina, IaR | 1 |
| Shetty, C | 1 |
| Balasubramani, M | 1 |
| Capps, N | 1 |
| Milles, J | 1 |
| Ramachandran, S | 1 |
| Benatar, JR | 1 |
| Stewart, RA | 1 |
| Steiner, G | 1 |
| Wilkinson-Berka, JL | 1 |
| Miller, AG | 1 |
| Gerich, JE | 1 |
| Hausenloy, DJ | 1 |
| Yellon, DM | 1 |
| Freyberger, H | 1 |
| Schifferdecker, E | 1 |
| Schatz, H | 1 |
| Evans, M | 1 |
| Anderson, RA | 1 |
| Graham, J | 1 |
| Ellis, GR | 1 |
| Morris, K | 1 |
| Davies, S | 1 |
| Jackson, SK | 1 |
| Lewis, MJ | 1 |
| Frenneaux, MP | 1 |
| Rees, A | 1 |
| Hernández-Mijares, A | 1 |
| Lluch, I | 1 |
| Vizcarra, E | 1 |
| Martínez-Triguero, ML | 1 |
| Ascaso, JF | 1 |
| Carmena, R | 1 |
| Farnier, M | 1 |
| Picard, S | 1 |
| Raslová, K | 1 |
| Nagyová, A | 1 |
| Dobiásová, M | 1 |
| Ptácková, K | 1 |
| Dusinská, M | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Fischer, S | 2 |
| Schmechel, H | 1 |
| Rothe, G | 1 |
| Schulze, J | 2 |
| Dude, H | 1 |
| Schwanebeck, U | 1 |
| Julius, U | 1 |
| Rössger, G | 1 |
| Lindner, J | 1 |
| Groh, G | 1 |
| Nehring, A | 1 |
| Capek, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
37 reviews available for clofibric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; D | 2008 |
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, | 2008 |
Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2009 |
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Li | 2010 |
[Diabetic dyslipoproteinemia: beyond LDL].
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy | 2009 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
[Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Topics: Clofibric Acid; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; | 2005 |
Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type | 2010 |
[Lipid therapy in patients with diabetes].
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dose-Response Relatio | 2010 |
Fibrates, glitazones, and peroxisome proliferator-activated receptors.
Topics: Animals; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Discovery; Dyslipidemias; Hi | 2010 |
Management of hypertriglyceridemia in the diabetic patient.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2010 |
LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Controlled Clinical Trials as | 2003 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-Co | 2004 |
Diabetic dyslipidaemia: insights for optimizing patient management.
Topics: Arteriosclerosis; Cardiovascular Agents; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopa | 2005 |
Outcome studies in type 2 diabetes.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Diabetes M | 2005 |
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflamm | 2005 |
Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Blood Coagulation Factors; Clofibric Acid | 2005 |
Lipids in type 2 diabetes.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; H | 2002 |
Role for fibrate therapy in diabetes: evidence before FIELD.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Metabolic Sy | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Ra | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovas | 2006 |
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Endothelium, Vascular; | 2006 |
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypol | 2006 |
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxy | 2006 |
[Favorable effects of decreasing lipids in patients with diabetes mellitus].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2006 |
Fibrates after the FIELD study: Some answers, more questions.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-Co | 2006 |
[Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates].
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Me | 2006 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Dia | 2007 |
Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Topics: Atherosclerosis; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglut | 2007 |
Update on the treatment of diabetic retinopathy.
Topics: Adrenal Cortex Hormones; Aldehyde Reductase; Angiotensin II; Antihypertensive Agents; Blood Glucose; | 2008 |
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Artery Disease; Diabetes Complications; Diabetes M | 2007 |
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Diseas | 2008 |
Diabetes: statins, fibrates, or both?
Topics: Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Huma | 2001 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
8 trials available for clofibric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Ty | 2009 |
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Topics: Adult; Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; | 2003 |
Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Topics: Adult; Anticholesteremic Agents; C-Reactive Protein; Clofibric Acid; Cytokines; Diabetes Mellitus, T | 2005 |
Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
Topics: Adult; Analysis of Variance; Area Under Curve; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, | 2000 |
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Topics: Adult; Aged; Apolipoproteins B; Area Under Curve; Arteriosclerosis; Blood Glucose; Carbohydrate Meta | 2000 |
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Diabeti | 1991 |
[Intensive basic therapy decreases the need for drug treatment and improves glucose control: an important result of the diabetes intervention study].
Topics: Clinical Trials as Topic; Clofibrate; Clofibric Acid; Combined Modality Therapy; Diabetes Mellitus, | 1988 |
9 other studies available for clofibric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2010 |
[On behalf and the extent of evidence].
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, | 2010 |
Enzymatic examination of potential interaction between statins or fibrates and consumed Tricholoma equestre.
Topics: Adult; Agaricales; Aged; Alanine Transaminase; Aspartate Aminotransferases; Clofibric Acid; Creatine | 2005 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type | 2007 |
The role of PPAR-alpha agonists in the prevention of CVD in diabetes.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type | 2007 |
Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipi | 2009 |
[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Topics: Adult; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fundu | 1994 |
Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
Topics: Blood Glucose; Cholesterol; Clofibric Acid; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; Fibr | 2000 |